ERK 1/2 is activated in non-small-cell lung cancer and associated with advanced tumours

British Journal of Cancer

Volumn 90, Issue 5, 2004, Pages 1047-1052

  Vicent, S ^a,b   Lopez Picazo J M ^b   Toledo, G ^b   Lozano, M D ^b   Torre, W ^b   Garcia Corchon C ^b   Quero, C ^b   Soria, J C ^c   Martin Algarra S ^b   Manzano, R G ^a   Montuenga, L M ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

EGFR; Ki 67; MAPK; NSCLC

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; NAVELBINE; PACLITAXEL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS EPITHELIUM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; ADENOCARCINOMA; CANCER STAGING; CELL NUCLEUS; COMPARATIVE STUDY; CYTOPLASM; ENZYME IMMUNOASSAY; EPITHELIUM; LUNG; LUNG TUMOR; LYMPH NODE METASTASIS; MEDIASTINUM TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CYTOPLASM; ENZYME ACTIVATION; EPITHELIUM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM STAGING; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 1942521000     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601644     Document Type: Article

References (35)

1. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, Murphy LC (2002) Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 8: 1747-1753
2. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson RI, Mendelsohn J, Baselga J (2001) Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61: 6500-6510
3. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110-124
4. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR (1995) PD 098059 is a specific inhibitor of the activation of mitogen activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489-27494
5. Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR (2003) Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 7: 647-654
6. Berger W, Setinek U, Mohr T, Kindas-Mugge I, Vetterlein M, Dekan G, Eckersberger F, Caldas C, Micksche M (1999) Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 83: 415-423
7. Blackball FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS, Shepherd FA (2003) Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 9: 2241-2247
8. Brognard J, Dennis P (2002) Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ 9: 893-904
9. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37-40
10. Cobb MH (1999) MAP kinase pathways. Prog Biophys Mol Biol 71: 479-500
11. Cohen CG, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G, Cerimele F, Govindarajan B, Macaron N, Arbiser JL (2002) Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8: 3728-3733
12. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni Jr JF (1995) Recent cancer trends in the United States. J Natl Cancer Inst 87: 175-182
13. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92: 7686-7689
14. Duncia JV, Santella III JB, Higley CA, Pitts WJ, Wityak J, Frietze WE, Rankin FW, Sun JH, Earl RA, Tabaka AC, Teleha CA, Blom KF, Favata MF, Manos EJ, Daulerio AJ, Stradley DA, Horiuchi K, Copeland RA, Scherle PA, Trzaskos JM, Magolda RL, Trainor GL, Wexler RR, Hobbs FW, Olson RE (1998) MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett 8: 2839-2844
15. Dy GK, Adjei AA (2002a) Novel targets for lung cancer therapy: part I. J Clin Oncol 20: 2881-2894
16. Dy GK, Adjei AA (2002b) Novel targets for lung cancer therapy: part II. J Clin Oncol 20: 3016-3028
17. Fong KM, Sekido Y, Minna JD (1999) Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 118: 1136-1152
18. Gee JM, Robertson JF, Ellis IO, Nicholson RI (2001) Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95: 247-254
19. Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284
20. Guddo F, Fontanini G, Reina C, Vignola AM, Angeletti A, Bonsignore G (1999) The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Hum Pathol 30: 788-794
21. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822
22. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J, Okamoto E, Hayashi N, Hori M (1998) Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27: 951-958
23. Levin WJ, Press MF, Gaynor RB, Sukhatme VP, Boone TC, Reissmann PT, Figlin RA, Holmes EC, Souza LM, Slamon DJ (1995) Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. Oncogene 11: 1261-1269
24. Mackeigan JP, Collins TS, Ting JP (2000) MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 275: 38953-38956
25. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR (1998) In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 153: 1411-1423
26. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U (2000) Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 89: 384-388
27. Mukohara T, Kudoh S, Yamauchi S, Kimura T, Yoshimura N, Kanazawa H, Hirata K, Wanibuchi H, Fukushima S, Inoue K, Yoshikawa J (2003) Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small cell lung cancer. Lung Cancer 41: 123-130
28. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M, Yoshida O (1995) Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55: 4182-4187
29. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810-816
30. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC (1997) Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483
31. Volm M, Koomagi R, Mattern J, Efferth T (2002) Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. Clin Cancer Res 8: 1843-1848
32. Webb CP, Van Aelst L, Wigler MH, Woude GF (1998) Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci USA 95: 8773-8778
33. Widmann C, Gibson S, Jarpe MB, Johnson GL. (1999) Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79: 143-180
34. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331
35. Xu JL, Lai R, Kinoshita T, Nakashima N, Nagasaka T (2002) Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 55: 530-534